Allergy Therapeutics (AGY) — Net Asset Quality Index
Allergy Therapeutics (AGY) has a Net Asset Quality Index of 6.0% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of GBX71.00 Million minus total liabilities of GBX66.75 Million yields net assets of GBX4.25 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read AGY total debt and obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Allergy Therapeutics Net Asset Quality Index Over Time (2002–2025)
This chart shows how Allergy Therapeutics's Net Asset Quality Index has evolved across 24 annual periods from 2002 to 2025. As of December 2025, the index stands at 6.0%, representing net assets of GBX4.25 Million against total assets of GBX71.00 Million GBX. For live market cap and overall valuation, see how much is Allergy Therapeutics worth.
Annual Net Asset Quality Index for Allergy Therapeutics (2002–2025)
The table below presents the year-by-year Net Asset Quality Index for Allergy Therapeutics from 2002 to 2025, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check AGY strategic asset allocation to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (GBX) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -41.7% | GBX-28.19 Million | GBX67.54 Million | GBX95.74 Million | ▼ -47.5 pp |
| 2024 | 5.7% | GBX3.71 Million | GBX64.83 Million | GBX61.12 Million | ▲ +2.6 pp |
| 2023 | 3.1% | GBX2.07 Million | GBX66.77 Million | GBX64.70 Million | ▼ -48.7 pp |
| 2022 | 51.8% | GBX37.77 Million | GBX72.95 Million | GBX35.18 Million | ▼ -3.3 pp |
| 2021 | 55.1% | GBX48.53 Million | GBX88.09 Million | GBX39.55 Million | ▲ +4.3 pp |
| 2020 | 50.8% | GBX43.78 Million | GBX86.22 Million | GBX42.44 Million | ▼ -4.1 pp |
| 2019 | 54.8% | GBX37.56 Million | GBX68.50 Million | GBX30.94 Million | ▲ +9.7 pp |
| 2018 | 45.2% | GBX23.03 Million | GBX51.02 Million | GBX27.98 Million | ▼ -7.3 pp |
| 2017 | 52.4% | GBX29.96 Million | GBX57.18 Million | GBX27.22 Million | ▼ -1.1 pp |
| 2016 | 53.5% | GBX30.32 Million | GBX56.68 Million | GBX26.36 Million | ▼ -14.5 pp |
| 2015 | 68.0% | GBX34.47 Million | GBX50.70 Million | GBX16.23 Million | ▲ +14.9 pp |
| 2014 | 53.1% | GBX15.07 Million | GBX28.40 Million | GBX13.32 Million | ▲ +2.4 pp |
| 2013 | 50.7% | GBX14.67 Million | GBX28.96 Million | GBX14.29 Million | ▼ -1.9 pp |
| 2012 | 52.6% | GBX14.59 Million | GBX27.75 Million | GBX13.16 Million | ▲ +45.6 pp |
| 2011 | 7.0% | GBX2.14 Million | GBX30.62 Million | GBX28.48 Million | ▼ -6.4 pp |
| 2010 | 13.3% | GBX3.89 Million | GBX29.11 Million | GBX25.23 Million | ▲ +118.3 pp |
| 2009 | -105.0% | GBX-23.18 Million | GBX22.08 Million | GBX45.25 Million | ▼ -56.3 pp |
| 2008 | -48.7% | GBX-11.29 Million | GBX23.18 Million | GBX34.47 Million | ▼ -84.5 pp |
| 2007 | 35.8% | GBX8.60 Million | GBX23.99 Million | GBX15.40 Million | ▼ -50.5 pp |
| 2006 | 86.3% | GBX32.70 Million | GBX37.88 Million | GBX5.18 Million | ▲ +11.0 pp |
| 2005 | 75.3% | GBX20.08 Million | GBX26.66 Million | GBX6.58 Million | ▲ +12.3 pp |
| 2004 | 63.0% | GBX7.08 Million | GBX11.23 Million | GBX4.16 Million | ▲ +13.2 pp |
| 2003 | 49.8% | GBX5.55 Million | GBX11.15 Million | GBX5.60 Million | ▲ +95.2 pp |
| 2002 | -45.5% | GBX-4.40 Million | GBX9.68 Million | GBX14.07 Million | — |